Supernus Pharmaceuticals' stock has risen 15% since my last "strong buy" rating, despite recent analyst downgrades due to Qelbree's slowing growth.Supernus' diverse neuroscience portfolio includes key...
Source LinkSupernus Pharmaceuticals' stock has risen 15% since my last "strong buy" rating, despite recent analyst downgrades due to Qelbree's slowing growth.Supernus' diverse neuroscience portfolio includes key...
Source Link
Comments